|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
1993-1-7
|
|
pubmed:abstractText |
A randomized trial was performed in premenopausal postoperative women with ipsilateral axillary node-positive (N+) breast carcinoma and known estrogen receptor (ER) status to assess the efficacy of an Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH)-based induction regimen and 5 or more years of tamoxifen (Tam).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1848-56
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:1453199-Adult,
pubmed-meshheading:1453199-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1453199-Breast Neoplasms,
pubmed-meshheading:1453199-Chemotherapy, Adjuvant,
pubmed-meshheading:1453199-Doxorubicin,
pubmed-meshheading:1453199-Female,
pubmed-meshheading:1453199-Humans,
pubmed-meshheading:1453199-Menopause,
pubmed-meshheading:1453199-Middle Aged,
pubmed-meshheading:1453199-Proportional Hazards Models,
pubmed-meshheading:1453199-Remission Induction,
pubmed-meshheading:1453199-Survival Analysis,
pubmed-meshheading:1453199-Tamoxifen,
pubmed-meshheading:1453199-Time Factors
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial.
|
|
pubmed:affiliation |
University of Wisconsin Clinical Cancer Center, Madison.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|
